Dear Colleagues,

Although carcinoma of the ovary affects women worldwide, the only effective treatment for ovarian neoplasia is limited to improving the patients’ survival and quality of life. Conventional cytotoxic agents have been at the center of treatment for more than three decades, but with disappointing clinical benefits. Hence, there is an urgent need for novel anticancer drugs to treat ovarian cancer patients. Recently, there has been hope for patients with specific germline mutations to receive targeted therapy. Clinical data reveal the effectiveness of these targeted drugs in fighting ovarian cancer. This special issue will highlight the discovery of novel targeted treatments for ovarian cancer, and is not limited to re-purposed drugs from other medication entities. In addition, this special issue will focus on three-dimensional and animal models to validate the efficacy of targeted drugs. Submissions describing the combination of conventional cytotoxic drugs with novel targeted drugs are encouraged, as well as those reporting the proteomic and phospho-proteomic profiles, both in vitro and in vivo, of ovarian cancer. 

Dr. Kenny Chitcholtan

Guest Editor